Status | Study |
Not yet recruiting |
Study Name: Relationship Between CETP Deficiency and Atherosclerosis in Patients With Hyperalphalipoproteinemia Condition: Low CETP Activity CETP Deficiency Hyperalphalipoproteinemi Date: 2013-07-22 |
Active, not recruiting |
Study Name: Mendelian Reverse Cholesterol Transport Study Condition: Cholesterol, HDL Lipid Metabolism, Inborn Errors Date: 2013-01-30 Interventions: Drug: 3H-cholesterol bound to albumin up to 100 uCi of [3H]-cholesterol (containing approximately 0.2 mg |
Active, not recruiting |
Study Name: Sitosterolemia Metabolism Condition: Sitosterolemia Date: 2012-04-16 Interventions: Drug: Ezetimibe 10mg ezetimibe/day, at least 4 months |
Completed |
Study Name: The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) Condition: Neutral Lipid Storage Disease Date: 2012-01-16 Interventions: Drug: Fibrate treatment Patients will receive a dosage of 400mg Bezafibrate every day during 28 weeks |
Completed |
Study Name: Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects Condition: Carnitine Palmitoyltransferase II Deficiency Very Long Chain Acyl Coa Dehydrogenase Deficien Date: 2009-09-23 Interventions: Drug: Bezafibrate 3 x 200 mg/ |
Completed |
Study Name: An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia Condition: Lipid Metabolism, Inborn Errors Hypercholesterolemia, Autosomal Date: 2008-06-05 Interventions: Drug: Mipomersen Sodium Subcutaneous injection as a single injection directly into the abdomen, thigh, o |
Completed |
Study Name: Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia Condition: Lipid Metabolism, Inborn Errors Hypercholesterolemia, Autosomal Date: 2008-01-22 Interventions: Drug: mipomersen 200 mg mipome |
Completed |
Study Name: Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia Condition: Lipid Metabolism, Inborn Errors Hypercholesterolemia, Autosomal Date: 2007-05-22 Interventions: Drug: mipomersen sodium 200 mg/ml, in 1 ml solution for subcutaneous injection. |
Completed |
Study Name: Measure Liver Fat Content After ISIS 301012 (Mipomersen) Administration Condition: Lipid Metabolism, Inborn Errors Hyperlipidemias Date: 2006-08-07 Interventions: Drug: mipomersen 200 mg subcut |
Active, not recruiting |
Study Name: Dietary Cholesterol and Defects in Cholesterol Synthesis in Mevalonate Kinase Deficiency Condition: Mevalonic Aciduria Mevalonate Kinase Deficiency Immune Sys Date: 2005-11-30 |